SERUM BIOMARKERS AND NON-INVASIVE INDICES FOR DISCRIMINATING MASLD AMONG ADULTS WITH DYSGLYCAEMIA

Creative Commons License

Ünal K.

IFCC WorldLab Congress 2026 – New Delhi, New Delhi, Hindistan, 25 - 29 Ekim 2026, ss.1, (Özet Bildiri)

  • Yayın Türü: Bildiri / Özet Bildiri
  • Basıldığı Şehir: New Delhi
  • Basıldığı Ülke: Hindistan
  • Sayfa Sayıları: ss.1
  • Gazi Üniversitesi Adresli: Evet

Özet

BACKGROUND / AIM
Adults with dysglycaemia are at
increased risk of MASLD.
Aim: identify imaging, anthropometric,
body-composition and biochemical
measures that distinguish MASLD
within a dysglycaemic population.METHODS
Cross-sectional study, ages 21–70.
MASLD-Dys, n=49
Dys without steatosis, n=11
Healthy controls, n=17
Ultrasonography assessed steatosis.
Samsung RS85 Prestige TAI/TSI
quantified USFF. TANITA BC-418MA
measured body composition.
ANOVA/Welch or Kruskal–Wallis with
adjusted post hoc tests. ROC cut-offs
maximised Youden’s J.MAIN FINDINGS
MASLD-Dys had higher USFF, BMI,
WC, TFM, FLI, TG and ALT than Dys.
Fasting glucose and HbA1c did not

differ significantly between MASLD-
Dys and Dys.

ELF was higher than in healthy controls.
FIB-4 and APRI did not differ
significantly among groups.CONCLUSION
Among dysglycaemic adults, MASLD
was associated with greater hepatic fat
and central/trunk adiposity.
USFF had the highest observed AUC.
FLI may offer a practical non-imaging
option.
These results concern MASLD
discrimination, not fibrosis staging. No
biopsy or elastography-based fibrosis
assessment was available.